U.S. markets closed

Sierra Oncology, Inc. (SRRA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
12.35+0.16 (+1.31%)
At close: 4:00PM EDT

Sierra Oncology, Inc.

885 West Georgia Street
Suite 2150
Vancouver, BC V6C 3E8
604 558 6536

Full Time Employees71

Key Executives

NameTitlePayExercisedYear Born
Dr. Barbara KlenckeChief Devel. Officer673.69kN/A1957
Dr. Mark M. KowalskiChief Medical Officer599.79kN/A1955
Dr. Stephen G. Dilly MBBS, Ph.D.Pres, CEO & DirectorN/AN/A1960
Mr. Sukhi Jagpal CA, CPA, CBV, MBAChief Financial OfficerN/AN/A1974
Ms. Emma McCannSr. VP of Operations & Program ManagementN/AN/AN/A
Dr. Keith E. AndersonSr. VP of Technical OperationsN/AN/A1969
Ms. Diane Kathleen GardinerSr. VP of HR & Admin.N/AN/AN/A
Ms. Christina Thomson J.D.Gen. CounselN/AN/AN/A
Dr. Wendy Chapman Ph.D.Sr. VP of Clinical OperationsN/AN/A1965
Dr. Gregg SmithSr. VP of Drug Devel.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has been investigated in two completed Phase 3 trials for the treatment of myelofibrosis. The company is also advancing SRA737, an orally bioavailable small molecule inhibitor Checkpoint kinase 1 is being investigated in two Phase 1/2 clinical trials; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was founded in 2003 and is headquartered in Vancouver, Canada.

Corporate Governance

Sierra Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.